Relay Therapeutics (RLAY) said Tuesday that the early Phase 2 data showed its experimental drug zovegalisib reduced lesion volume in patients with rare vascular anomalies linked to PIK3CA mutations.

In the ReInspire trial, 60% of evaluable patients achieved a volumetric response within 12 weeks, while nearly all patients saw symptomatic improvement, Relay said. The study, according to Relay, enrolled adults and adolescents with conditions including PIK3CA-related overgrowth spectrum and lymphatic malformations.

The company said the treatment showed a manageable safety profile at lower dose levels, supporting potential long-term use. Relay said it is continuing enrollment in expansion cohorts and advancing a late-stage breast cancer study for zovegalisib.